Initial study is enrolling healthy patients across seven cohorts to assess safety, tolerability, and pharmacokinetic profile related to ML-007 therapy SAN FRANCISCO, February 2, 2022 – MapLight Therapeutics announced it has initiated a Phase 1 clinical trial evaluating ML-007, a novel therapeutic developed to target circuits understood to be dysfunctional in neurologic conditions such as … Continued
Creating innovative therapeutics for serious CNS disorders
MapLight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Our Motivation
Though the brain plays such a critical role in our bodies, it’s interconnections have until recently been poorly understood. Consequently, very few targeted medications have been developed to help those suffering from serious central nervous system (CNS) disorders. Significant unmet medical need persists in this area, and the field has seen little innovation in the advancement of effective therapies. More
Our Platform
We’re on the forefront of developing more effective therapeutics for CNS disorders, focusing on critical neural circuits associated with the defining symptoms of disease. More
Our Clinical Programs
We have advanced our Autism program into a Phase 1 clinical trial, with many more programs under development. More
News
The $1.75M award builds on a $5.5M grant from MJFF announced earlier this month. MapLight also received an $8.1M award from MJFF in 2020. SAN FRANCISCO, CA, Aug. 25, 2021 – MapLight Therapeutics announced a $1.75M million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new therapies for the treatment … Continued